BlossomHill Therapeutics, Inc. Share Price

Stocks

Real-time Estimate Cboe BZX 17:36:46 15/10/2026 BST			5-day change	1st Jan Change
15.01 ^USD	-1.64%		-10.99%	-

09-28	Blossomhill Therapeutics, Inc. Presents Preclinical Data on Novel Pan-KRAS Inhibitor, Bh-501284, At the AACR Conference on Pancreatic Cancer	CI
09-20	BlossomHill Therapeutics, Inc.(NasdaqGS:BLSM) added to S&P TMI Index	CI

NasdaqUSD

Markets		Quality
Nasdaq	BLSM	Delayed
CBOE	BLSM	Real-time

09-28	Blossomhill Therapeutics, Inc. Presents Preclinical Data on Novel Pan-KRAS Inhibitor, Bh-501284, At the AACR Conference on Pancreatic Cancer	CI
09-20	BlossomHill Therapeutics, Inc.(NasdaqGS:BLSM) added to S&P TMI Index	CI
09-18	BlossomHill Therapeutics Q2 Loss Widens	MT
09-18	Earnings Flash (BLSM) BlossomHill Therapeutics Posts Q2 Loss $8.75 a Share	MT
09-18	BlossomHill Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
09-15	BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 Solara Trial Demonstrating Anti-Tumor Activity of Omni-EGFR Inhibitor BH-30643 in EGFR C797s-Positive NSCLC	CI
09-15	BlossomHill Drug Shows 45% Response Rate in Lung Cancer Trial	MT
09-01	Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target	MT
09-01	JPMorgan Initiates BlossomHill Therapeutics at Overweight	MT
09-01	Guggenheim Initiates BlossomHill Therapeutics at Buy With $30 Price Target	MT
09-01	HC Wainwright Initiates BlossomHill Therapeutics at Buy With $35 Price Target	MT
08-18	BlossomHill Says BH-30643 Gets FDA Fast Track Designation in Non-Small Cell Lung Cancer	MT
08-18	Blossomhill Therapeutics Receives Fda Fast Track Designation for Bh-30643 for Treatment of Advanced Egfr C797s-Positive Nsclc	CI

09-01	Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target	MT
09-01	JPMorgan Initiates BlossomHill Therapeutics at Overweight	MT
09-01	Guggenheim Initiates BlossomHill Therapeutics at Buy With $30 Price Target	MT
09-01	HC Wainwright Initiates BlossomHill Therapeutics at Buy With $35 Price Target	MT

09-28	BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer	GL
09-28	BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer	AQ
09-18	BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results	GL
09-15	BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer	GL
09-03	BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference	GL

Manager	Title	Age	Since
Jing Rong Jean Cui CEO	Chief Executive Officer	62	31/05/2020
Jason Keyes DFI	Director of Finance/CFO	55	30/04/2025
Zachary Zimmerman CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Jing Rong Jean Cui BRD	Director/Board Member	62	31/05/2020
Bihua Chen BRD	Director/Board Member	57	31/01/2021
Yi Shan Li CHM	Chairman	61	31/05/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/08/26	Sundeep Agrawal	Conversion	Director	1,157,048	3.6917%
10/08/26	Cormorant Asset Management LP	Conversion	Company	6,915,568	22.0651%
10/08/26	Vincent Liptak	Buy	General Counsel	47,574	0.1518%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BLOSSOMHILL THERAPEUTICS, INC.	-1.64%	-10.99%	-	-	485M
WUXI APPTEC CO., LTD.	+0.21%	-7.67%	+61.07%	+71.32%	68.92B
ARGENX SE	+1.66%	+7.51%	+8.12%	+61.40%	51.9B
LONZA GROUP AG	+3.14%	+7.17%	+12.48%	+41.70%	48.73B
IQVIA HOLDINGS INC.	+2.84%	+4.08%	+32.66%	+35.42%	43.13B
REVOLUTION MEDICINES, INC.	-1.37%	+1.87%	+286.69%	+461.68%	41.48B
BEONE MEDICINES AG	+5.44%	+6.15%	+17.56%	+113.68%	39.96B
CELLTRION, INC.	+1.28%	-0.76%	+12.67%	+45.10%	30.6B
WUXI BIOLOGICS (CAYMAN) INC.	-2.21%	-14.22%	+40.33%	-0.94%	26.01B
BIONTECH SE	+1.75%	-2.06%	-13.59%	-7.02%	22.27B
Average	+1.11%	-4.32%	+50.89%	+91.37%	37.35B
Weighted average by Cap.	+1.48%	-3.50%	+54.62%	+98.00%